Sanofi SA Surges in Q1 2025 with Strong Revenue Growth Led by Dupixent Success
Sanofi SA kicked off 2025 with a strong performance, reporting a 10.8% increase in revenue and exceeding expectations, driven by the success of its flagship product Dupixent and other new pharmaceutical launches.
2 minutes to read